

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 55701-004002	Application No. 10/798,119
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Yih-Lin Chung	
		Filing Date 3/11/2004	Group Art Unit 1614

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	20050171206	08/2005	Brahe et al.			
	AB	20060251689	11/2006	Weidner			
	AC	20030147926	08/2003	Ebert et al.			
	AD	2003/0134865	07/2003	Adcock et al.			
	AE	2003/0114525	06/2003	Kammer et al.			
	AF	2003/0082666	05/2003	Kammer et al.			
	AG	6,548,479	04/2003	Skov			
	AH	6,403,555	06/2002	Skov			
	AI	6,124,495	09/2000	Neiss et al.			
	AJ	5,993,845	11/1999	Geerts et al.			
	AK	5,605,930	02/1997	Samid			
	AL	5,281,623	01/1994	Clemens et al.			
	AM	6,225,294	05/2001	Daifotis et al.			
	AN	6,313,091	11/2001	Wisniewski et al.			
	AO	2001/0009922	07/2002	Faller			
	AP	5430064	07/1995	Hirsch et al.			
	AQ	2001/0021700	09/2001	Moore et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AR	WO 98/29109	09/1998	WIPO				
	AS	WO 01/17514	03/2001	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AT	CHUNG et al. "Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy" Molecular Cancer Therapeutics 2004;3(3):317-325

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 55701-004002	Application No. 10/798,119
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Yih-Lin Chung	
		Filing Date 3/11/2004	Group Art Unit 1614

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AU	Mishra et al., "Histone Deacetylase Inhibitor Trichostatin A as a Strong Candidate for Treatment of Systemic Lupus Erythematosus," FASEB Journal, 5:A1214, March 2001.
	AV	Mishra et al., "Trichostatin A Reverses Skewed Expression of CD154, Interleukin-10, and Interferon-Gamma Gene and Protein Expression in Lupus T Cells," Proceedings of the National Academy of Sciences of USA 98(5):2628-2633, (2001)
	AW	Richon et al., "Histone Deacetylase Inhibitor Selectively Induces P21 WAF1 Expression and Gene-Associated Histone Acetylation," PNAS, 97(18):10014-10019, August 28, (2000)
	AX	Witt et al., "Induction of Fetal Hemoglobin Expression by the Histone Deacetylase Inhibitor Apicidin," Blood 101(5), March 1, (2003)
	AY	www.merriam-webster.com/dictionary/prevent , 11/13/2007.
	AZ	Goldring et al., Mechanisms of Bone Loss in Inflammatory Arthritis: Diagnosis and Therapeutic Implications, Arthritis Res 2000, 2:33-37.
	AAA	Stoilov et al., "Inhibition of Repair of X-ray-induced DNA Double-Strand Breaks in Human Lymphocytes Exposed to Sodium Butyrate," <i>International Journal of Radiation Biology</i> Vol. 76, No. 11, pp 1485-1491 (2000)
	ABB	Miller et al., "Modulation of Radiation Response of Human Tumour Cells by the Differentiation Inducers, Phenylacetate and Phenylbutyrate," <i>International Journal of Radiation Biology</i> Vol. 72, No. 2, pp 211-218 (1997)
	ACC	Saunders et al., "Histone Deacetylase Inhibitors as Potential Anti-Skin Cancer Agents," <i>Cancer Research</i> Vol. 59, pp 399-404 (1999)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	